Abstract
BRCA1 and BRCA2 tumor suppressor genes are central components of the homologous recombination (HR) DNA repair pathway, a high-fidelity process required to maintain genome integrity in the presence of DNA damaging agents. Germline or somatic mutation in BRCA1 or BRCA2, and methylation of BRCA1 therefore strongly influence response of patients with high-grade serous ovarian cancer (HGSC) to chemotherapy or poly ADP ribose polymerase inhibitors (PARPi). The profound sensitivity of HR-defective HGSC to chemotherapy and PARPi provides a strong selective pressure for tumor cells that have partially or wholly restored HR repair function. Here we focus on mechanisms by which restoration of activity of mutant or methylated BRCA genes occurs, how it is detected, and some unresolved issues requiring attention before this important biomarker can be fully utilized to improve HGSC patient management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
